Live attendance at SeaStar Medical's Nov. 11 results call requires preregistration.

SeaStar Medical (ICU) will report Q3 2026 results on Nov. 11, 2026, with a live call requiring preregistration. The company focuses on treatments for organ failure, with one FDA-approved product and ongoing clinical trials. ICU's SCD therapy has Breakthrough Device Designation for seven indications.

Original reporting
Published Nov 4, 2026, 1:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ICU
Neutral
high confidence
Mentioned
$ICU
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ICUNeutralLow
01

Why it matters

The announcement itself is low‑impact; traders will watch for the actual earnings release for actionable information.

02

Market read

The article provides only the timing of an upcoming earnings call, offering limited immediate trading relevance.

03

What to watch

Potential updates on the NEUTRALIZE‑AKI trial could be disclosed during the call, which may surprise the market.

Relevance 4/10Novelty 3/10Timing: pre‑market on Nov 11 2026

Background

SeaStar Medical is a commercial‑stage biotech focused on acute kidney injury treatments. The company’s Q3 results are scheduled for Nov 11, 2026.

Company-level read

Ticker impact

$ICUNeutralHigh confidence
Context

SeaStar Medical announced the date and time of its Q3 results call on Nov. 11, 2026.

Expected impact

neutral impact as the market already anticipates the upcoming earnings release

Evidence & confidence

No earnings numbers or guidance were disclosed; only the timing of the call was provided.

Market effects

None; the announcement does not affect the broader healthcare sector.

Limited to investors tracking SeaStar Medical.

Minimal; the news is company‑specific.

Counterpoint

If the market expects weak Q3 results, the call announcement could trigger a short‑cover rally ahead of the release.

Key entities

  • SeaStar Medical Holding Corporation

    US‑listed biotech (Nasdaq: ICU) reporting Q3 results.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p